Detalhe da pesquisa
1.
Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.
Clin Cancer Res
; 25(17): 5231-5241, 2019 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31171545
2.
Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.
Cancer Immunol Res
; 6(6): 658-670, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29622580
3.
A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.
Blood Transfus
; 13(3): 464-71, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-25761309
4.
MHV-68 producing mIFNα1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68.
Vaccine
; 29(23): 3935-44, 2011 May 23.
Artigo
Inglês
| MEDLINE | ID: mdl-21481326
5.
Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
J Immunol
; 170(10): 5195-202, 2003 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12734367